Purgo Scientific

Executive Summary

Purgo Scientific is a preclinical-stage medical device company developing the Purgo Pouch, a localized, sustained drug delivery system designed to treat orthopedic biofilm infections, particularly fracture-related infections (FRI). The technology directly delivers antibiotics to the surgical site, aiming to disrupt biofilms and reduce surgical site infections (SSIs). With orthopedic biofilm infections representing a significant unmet need due to antibiotic resistance and poor outcomes, Purgo's approach could improve patient outcomes and lower healthcare costs. The company is based in San Diego and was founded in 2018. While still in preclinical development, Purgo Scientific has the potential to address a critical gap in orthopedic infection management if clinical validation is successful. The company remains privately held with limited public information on funding or valuation.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical proof-of-concept studies for Purgo Pouch70% success
• Q1 2027FDA pre-submission meeting to discuss Investigational Device Exemption (IDE) pathway60% success
• Q2 2027Series A financing round to support first-in-human trials50% success